AAD: Continuous Improvements Seen Through 68 Weeks for Deuruxolitinib in Alopecia
Proportion of patients achieving Severity of Alopecia Tool score ≤20 increased through 68 weeks of open-label extension
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.